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ABSTRACT
The influence of HAART on the evolution to cervical squamous intraepithelial lesions (SIL) among HIV
women with a normal cytological test in the HAART era was studied. A retrospective cohort study (1997–2005)
of HIV-infected women treated with HAART was conducted. Those with a normal cervical cytology (Papan-
icolaou test) and at least one subsequent test were included. Survival (time until diagnosis of SIL), univari-
ate, and multivariate analyses were performed. A total of 133 HIV-infected patients treated with HAART
were included. The incidence of SIL was 35% (47 patients). SIL was diagnosed in 36 of 110 (33%) patients
with a baseline and final immunological status of 200 CD4 cells/l and in 6 of 9 (67%) patients with a base-
line and final immunological status of 200 CD4 (OR: 0.24, 95% CI: 0.06–1.03, p  0.041). SIL was diag-
nosed in 10 of 60 (17%) patients with an undetectable baseline and final HIV viral load and in 36 of 70 (51%)
patients with a detectable HIV viral load (OR: 0.19, 95% CI: 0.07–0.46, p  0.001). A high incidence of SIL
(cancer precursor lesions) was observed among HIV women without a background of cervical pathology.
The effect of HAART on the control of HIV replication and of immunological status (200 CD4) through the
follow-up was associated with a reduction of SIL.
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INTRODUCTION
CERVICAL SQUAMOUS INTRAEPITHELIAL LESIONS (SIL) are pre-cursors to invasive cervical cancer, which has been shown
to be related to human papillomavirus (HPV) infection.1,2 HIV
infection may increase the risk of HPV infection, promote the
reactivation of a latent infection, or permit infection persistence.
Indeed, HPV infection is more prevalent and persistent in HIV
women, which thereby contributes to a higher risk for invasive
cervical cancer and its precursor lesions. Likewise, some data
have suggested that about 20% of HIV women without evi-
dence of cervical disease will develop SIL within 3 years.3–5
Highly active antiretroviral therapy (HAART) controls HIV
replication and improves immunological status by increasing
CD4 cell counts. Theoretically, this immune restoration could
reduce the risk of cervical SIL, delaying or normalizing the evo-
lution of cervical cytological changes. However, HAART also
prolongs life expectancy; this might increase the probability of
HPV exposure and the accumulation of genetic somatic muta-
tions, thereby increasing the probability of developing cervical
disease. But these possibilities have not yet been confirmed.
Limited and contradictory data are available on the evolution
of cervical cytological changes in HIV women treated with
HAART,6–15 and the role of HAART in the incidence of cer-
vical SIL among HIV women without cervical HPV-related
pathology is not well established.
On the other hand, cervical cytology is undoubtedly the most
suitable diagnostic technique and has contributed dramatically
to the reduction in mortality related to cervical cancer. Atypi-
cal squamous cells of undetermined significance (ASCUS), the
most common abnormal finding of cervical cytological testing,
is an outcome with an uncertain meaning that even expert cy-
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topathologists are unable to classify as reactive alterations or
as premalignant lesions.16,17 The etiology and the outcomes of
ASCUS are uncertain, as the name implies, and limited data on
ASCUS are available.18,19
Therefore, the objective of this retrospective study was to
generate data about the long-term effect of HAART on the in-
cidence of cervical SIL among HIV women with a normal
baseline cytological test and without a previous history of cer-
vical pathology, as well as to generate data about the evolution
of lesions (regression or progression) in patients who were di-
agnosed with ASCUS.
MATERIALS AND METHODS
Between January 1997 and December 2005, all patients in-
cluded in the database of the HIV Clinical Unit of the Germans
Trias i Pujol University Hospital were evaluated. HAART ther-
apy became widely available in our hospital at the beginning
of 1997, so this was considered the starting point of the study.
The patients eligible for the study had to fulfill the follow-
ing inclusion criteria: women with an HIV diagnosis and two
consecutive normal cervical cytological tests [Papanicolaou
(Pap) test] and at least one subsequent test and women who
were treated with HAART between cytologies were included
in the study. The exclusion criteria included having a previous
history of cervical dysplasia or a cancer diagnosis.
The following data were also gathered at baseline: date of
birth, date of cervical cytologies, date of HIV diagnosis,
CD4 cell count (1 month from the date of a normal Pap
test), CD4 nadir previous to inclusion, HIV viral load
(HIV_VL) (1 month from the date of a normal Pap test),
HAART previous to inclusion, number of sexual partners,
number of patients with a history of pregnancies and other
risk factors such as intravenous drug abuse, and a history of
smoking. Likewise, the following data were gathered between
cytologies: CD4 nadir, CD4 cell count (1 month from the
date of Pap test), HIV_VL (1 month from the date of Pap
test), and information on the patients’ treatment with
HAART, which was strictly checked. HAART included at
least two nucleoside reverse transcriptase inhibitors in com-
bination with either a protease inhibitor or a nonnucleoside
reverse transcriptase inhibitor.
Study design
This was a retrospective cohort study, based on the cohort
of outpatient women treated by the gynecologists (A.T., N.G.)
of the HIV Unit of a university tertiary hospital.
Cervical cytology
The Pap test was the standard diagnostic technique used rou-
tinely in gynecological examination. The cytological changes
were classified according to the Bethesda System16: normal, no
cell changes; ASCUS, atypical squamous cells of unknown sig-
nificance; LSIL, low-grade squamous intraepithelial lesions;
and HSIL, high-grade squamous intraepithelial lesions. Usu-
ally, all samples were checked by two cytopathologists (M.L.,
E.C.). Generally, when a patient is diagnosed with a squamous
intraepithelial lesion (low or high), a colposcopy and biopsy are
proposed in order to verify the cytological result and to pro-
ceed to conization if the biopsy confirms an HSIL or carcinoma.
Due to the fact that ASCUS is an outcome with an uncer-
tain meaning and is difficult to classify (even by expert cy-
topathologists), and in order to avoid possible background
noise, it was analyzed independently.
Influence of HAART effect on immunological status
(CD4) and on HIV viral load, and its impact on the
evolution from a normal cervical cytological test 
to SIL
To study the impact of HAART on the evolution from a nor-
mal cervical cytological test to SIL, the patients were divided
according to the value of baseline and final CD4 lymphocyte
count (200 and 350 cells/l) and according to the value of base-
line and final HIV_VL (undetectable 50 copies).
The following requirements were considered to perform the
survival analysis, time until SIL. The baseline moment was the
date of the normal cytology test. When a cervical cytology of
SIL (or carcinoma) was diagnosed, the date of this Pap test was
used for survival analysis (time until SIL). This information had
to be confirmed with a subsequent positive result from the his-
tology (biopsy), or if it was not available, with a second posi-
tive Pap test result. If the patient did not present any change,
that is, if the patient presented several successive normal Pap
test results, the date of the last test available in the database
was considered for survival analysis (censored time).
Influence of HAART on the evolution from an ASCUS
diagnosis to a normal cervical cytological test
(regression) or to SIL or carcinoma (progression)
This second study was focused on establishing data about
the evolution o ASCUS, thereby providing information about
the significance of ASCUS cytology in HIV-positive women.
The following requirements were followed to study the evolu-
tion of an ASCUS diagnostic. All women included in the pre-
vious analysis who were diagnosed with ASCUS and with at
least one subsequent Pap test result were considered for this
one. If the patient did not present any change, that is, if the pa-
tient remained with successive ASCUS Pap test results, the date
of the last test available in the database was considered for the
analysis. If the patient presented a normal Pap test result after
the ASCUS diagnostic, another Pap test was necessary in or-
der to verify this result. If the Pap test showed an SIL (or car-
cinoma), the result had to be confirmed with a subsequent pos-
itive result from the histology (biopsy), or if it was not available,
with a second positive Pap test result.
Statistical analysis
A descriptive analysis was performed by baseline popula-
tion. Continuous data are summarized as mean  standard de-
viation (minimum; maximum).
The evolution of cervical cytology (SIL incidence during fol-
low-up) was studied with Kaplan–Meier curves and the differ-
ences were assessed with the Mantel–Haenzel log-rank test, the
Breslow test, and the Tarone–Ware test. Univariate analysis and
multivariate proportional hazards regression (Cox regression)























































would predict SIL: age, age of cervical cytology, time of HIV
diagnosis, baseline CD4, CD4 nadir (previous inclusion and be-
tween cytologies), HIV_VL, HAART previous inclusion, num-
ber of partners, history of pregnancies, and other risk factors
such as intravenous drug abuse and tobacco use. Odds ratios
(OR) and Hazards ratios (HR) comparing SIL diagnosis and
their corresponding 95% confidence intervals (95% CI) were
estimated. A p value of 0.05 was considered statistically sig-
nificant.
All data were recorded in a database program (Microsoft Ac-
cess for Windows XP, Redmont, CA). Data analysis was per-
formed using the statistical software programs SPSS for Win-
dows version 12.0 (Apache Software Foundation, SPSS Inc.,




One hundred and thirty-three patients, who met the inclusion
and exclusion criteria, were included in the study during the pe-
riod between January 1997 and December 2005. Baseline pa-
tient characteristics are summarized in Table 1. The average
time to SIL development was 902  689 days (min: 65; max:
2808). The average number of visits between baseline and fi-
nal cytologies was 4.6  3.1 (min: 2; max: 18). SIL was diag-
nosed in 47 of 133 (35% ) patients. Figure 1 shows the actuar-
ial probability (Kaplan–Maier curve) of remaining free of SIL.
Effect of HAART on immunological status (CD4) and
its impact on the cervical cytological evolution
SIL was diagnosed in 6 of 9 (67% ) patients with a baseline
and final immunological status of 200 CD4 cells/l, in 5 of
11 (46%) with 200 CD4 at baseline and 200 CD4 at the fi-
nal analysis, and 36 of 110 (33% ) with a baseline and final im-
munological status of 200 CD4. Three patients with 200
CD4 at baseline and 200 CD4 at the final analysis did not de-
velop SIL. Therefore, the percentage of patients developing SIL
varied according to immunological status. Figure 2A shows the
actuarial probability (Kaplan–Maier curve) of remaining free
of SIL in the groups of patients stratified by immunological sta-
tus (200 CD4) between cytologies (log rank, p  0.012; Bres-
low, p  0.014, Tarone–Ware, p  0.012). Univariate analysis
showed that undetectable baseline HIV_VL (OR: 0.13, 95% CI:
0.06–0.31, p  0.001) and baseline CD4 cell count were inde-
pendent predictive factors for remaining free of SIL. Table 2
shows the number and percentages of patient diagnoses of SIL
during the complete follow-up period grouped by baseline CD4
lymphocyte count (cells/l). The actuarial probability of re-
maining free of SIL in the groups of patients stratified by base-
line CD4 lymphocyte count of 350 cells was 53% in the group
of 350 CD4 baseline group and 70% in the 350 CD4 base-
HAART AND CERVICAL CYTOLOGIC CHANGES 967
TABLE 1. BASELINE CHARACTERISTICS OF THE
POPULATION INCLUDED IN THE STUDYa
Baseline characteristics n  133
Age (years) (mean  SD) 34.8  8.7
Older than 40 years old [n (%)] 15 (11.3%)
HIV-1 RNA load (copies/ml) (mean  SD) 6776  31617
CD4 cell count cells/l (mean  SD) 502  295
200 cells/l [n %)] 20 (15.0%)
200 and 350 cells/l [n %)] 23 (17.3%)
350 and 500 cells/l [n %)] 30 (22.6%)
500 cells/l [n %)] 60 (45.1%)
HAART previous to inclusion 47 (35.3%)
Time of known HIV infection (years) 6.0  3.9
Number of partners (mean  SD) 12.8  40.5
Patients with history of pregnancies [n %)] 60 (45.1%)
aPatients with normal cervical cytology (Papanicolaou test) and with-

























FIG. 1. The actuarial probability (Kaplan–Meier curve) of re-
maining free of SIL in patients with normal baseline cervical






















































line group (log rank, p  0.04; Breslow, p  0.03, Tarone–
Ware, p  0.03). Similar results were obtained when the pa-
tients were stratified by a baseline CD4 cell count of 200. In
contrast, SIL was diagnosed only in 12 of 47 (26% ) patients
with 200 CD4 nadir between cytologies (p  0.412). Similar
results were obtained on the cervical cytological evolution when
the cut-off of immunological status used was 350 CD4 nadir
lymphocyte cells between cytologies.
Effect of HAART on HIV viral load and its impact on
cervical cytological evolution
Three patients were lost to this analysis. SIL was diagnosed
in 34 of 65 (52% ) patients with detectable HIV_VL at base-
line and at the final Pap test; in 2 of 5 (40% ) with an unde-
tectable baseline HIV_VL but who were detectable at the end;
in 7 of 49 (14% ) with detectable baseline and undetectable fi-
nal HIV_VL; and in 3 of 11 (27% ) with undetectable baseline
and final HIV_VL. So, SIL was diagnosed in 10 of 60 (17% )
patients with undetectable HIV_VL between cytologies or with
undetectable HIV_VL at the final cytology test, and in 36 of
70 (51% ) patients with detectable HIV_VL (OR: 0.19, 95%
CI: 0.07–0.46, p  0.001). The distribution of these 70 patients
according to their detectable HIV_VLV at final Pap test was
49 patients between 50 and 400 copies; 10 patients between
400 and 10,000 copies; and 10,000 copies: 11 patients.
Of patients 56% (39 out of 70) presented with bad treatment
compliance and 84% (26 out of 31) with treatment resistance.
Figure 2B shows the actuarial probability of remaining free of
SIL in the patients grouped by baseline and final HIV_VL (log
rank, p  0.001; Breslow, p  0.001, Tarone–Ware, p 
0.001). Univariate analysis, but not multivariate analysis (Cox
regression analysis), showed that an undetectable baseline
HIV_VL (OR: 0.13, 95% CI: 0.06–0.31, p  0.001) was an in-
dependent predictive factor for remaining free of SIL. Age, age
of cervical cytologies, time of HIV diagnosis, CD4 nadir, num-
ber of sexual partners, and history of pregnancies were not sig-
nificantly associated with the risk of developing SILs.
Influence of HAART on the evolution from an ASCUS
diagnosis to a normal cervical cytological test
(regression) or to SIL or carcinoma (progression)
An ASCUS diagnosis was detected in 55 (41% ) patients af-
ter previous normal Pap test results. The average time from nor-
mal cytology to ASCUS was 737  691 days (min: 99; max:
2275). Only 26 of 55 (47% ) patients fulfilled the requirements
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TABLE 2. NUMBER (PERCENTAGE) OF PATIENTS DIAGNOSED WITH SIL
GROUPED BY BASELINE CD4 LYMPHOCYTE COUNT (CELLS/L)
CD4  500 CD4  500 CD4  350 CD4  350 CD4  200 CD4  200
n n n n n n
(%) (%) (%) (%) (%) (%)
18/60 29/73 27/90 20/43 36/113 11/20
(30.0%) (39.7%) (30.0%) (46.5%) (31.9%) (55.0%)
OR (95% CI) 0.65 (0.32–1.34), p  0.24 0.49 (0.23–1.04), p  0.06 0.38 (0.14–1.01), p  0.05
FIG. 2. The actuarial probability (Kaplan-Meier curve) of remaining free of SIL. (A) According to the value of baseline and























































those, only a descriptive analysis was performed. None of these
26 patients with an ASCUS diagnosis progressed to SIL; in 21
(81% ) patients the ASCUS lesion regressed to a normal Pap
test, and 5 (19% ) patients continued to have an ASCUS diag-
nostic. The average time from ASCUS to a normal Pap test (re-
gression) was 226  205 days (min: 56; max: 974), and the av-
erage time from ASCUS to ASCUS (no change) was 317 
378 (min: 92; max: 992). Five of these 26 patients were diag-
nosed as ASC-H (high-grade atypical squamous cells) at base-
line, 3 regressed to normal cytology, and 2 maintained the di-
agnosis at follow-up.
DISCUSSION
Our study has assessed the “natural history” and the inci-
dence of cervical SILs among a cohort of HIV women with-
out a background of cervical pathology. Although this is a ret-
rospective study, and it must be interpreted with caution, our
results suggest that the incidence of SIL (cancer precursor le-
sions) was higher than expected, but that an immunological sta-
tus of 200 CD4 cells and an undetectable HIV viral load could
have a protective role for SIL development.
Limited data are available on the natural history of cervical
pathology related to HPV infection in patients on HAART.
Some previous data had suggested that about 20% of HIV
women without evidence of cervical disease will develop SIL
within 3 years.3–5 In our study, the incidence of SIL was higher
than expected (35% ) in spite of being a cohort of HIV-infected
women treated with HAART. The design of our study, the pe-
riod of follow-up, races, or geographical differences could over-
estimate the result obtained. But this result could also suggest,
in contrast to other HIV-associated malignancies, that the over-
all effect of HAART on the course of cervical HPV-related
pathology is not clear. Indeed, the long-term effect of HAART
on the incidence of cervical pathology is unknown, and its ef-
fect on the likelihood of progression to cervical cancer is con-
troversial.6–15 HIV_VL may involve interactions between HIV
and HPV at the molecular level,20–22 and higher HIV loads have
been associated with a reduced likelihood of SIL regression.23
Then the impact of the effect of HAART on obtaining or main-
taining an undetectable HIV_VL status could be related to a re-
duced incidence of SIL, despite the high incidence of SIL found
in our study. As well, our results highlight the fact that im-
proving or maintaining a good immunological status as a con-
sequence of HAART was related to a reduction in the incidence
of SIL. That is, immunological status was an important factor
in predicting the risk of SILs, suggesting that the boundary of
immunodeficiency is between 200 and 350 cells/l. This find-
ing is consistent with previous studies.24–26 In fact, HIV-asso-
ciated cell-mediated immunodeficiency is a factor in predicting
the incidence of SILs and in influencing the likelihood of pro-
gression of cytological cervical lesions.27 The immunodefi-
ciency may increase the risk of SILs by permitting HPV per-
sistence,24,28,29 or by accelerating the transit time to SILs.30
Actually, SILs are inversely associated with CD4 lymphocyte
counts among HIV women.27
The etiology and the outcomes of ASCUS are uncertain, as
the name implies, and limited data on ASCUS are avail-
able.16–19 Although the small number of patients analyzed in
our study did not allow us to derive conclusions, an ASCUS
diagnosis was the most common cervical abnormality (inci-
dence of 41% ASCUS diagnosis versus 35% SIL diagnosis),
and this result is in accordance with those of a previous study.19
But, by contrast to this previous study, none of the patients an-
alyzed progressed to SIL and 81% of them regressed to a nor-
mal cervical Pap test. These findings could suggest that an AS-
CUS diagnosis reflects a benign or reactive process, or that
HAART could avoid the ASCUS progression in patients pre-
viously treated with HAART as well as after the ASCUS di-
agnosis.
On the other hand, the role of cervical mucosa immunity in
HPV-related cervical disease is poorly understood, and a poor
immunological status could reflect a bad cervical mucosal im-
mune mechanism important to the natural control of an HPV
infection.31 This study evaluates only the indirect effect of
HAART on cervical pathology, as outcome on its effect on im-
munological status or its effect on HIV viral load. The cervi-
cal cytology is the consequence of HPV infection. Thus, it is
likely that once the HPV virus genetically alters the epithelial
cell, the genetic material of the lesion is irreparable, despite im-
mune recovery or improvement achieved with HAART. That
is, in spite of immunological recovery, the epithelial cell can-
not revert to a normal healthy state once an SIL has formed.32
Likewise, this study does not allow the determination of
whether HAART has some direct effect on HPV, on epithelial
cells, on local immunity, or on the balance between cell pro-
liferation and apoptosis. This is significant because these are
important issues that could contribute to the elucidation of the
actual role of HAART in this coinfection, in addition to help-
ing to understand why in our cohort the incidence of SIL was
higher than expected.
A few limitations of this study should be acknowledged. We
have analyzed time until the event (SILs) accepting that the date
of the Pap test is the moment that the event is occurring. Our
data set was obtained from the database derived from the elec-
tronic medical history of HIV outpatients; therefore the data
set retrospectively reflected the clinical routine. Although a cer-
vical cytological screening routine is established in our center,
we could not assume that all women would adhere to screen-
ing and systematic follow-up. Likewise, previous studies have
demonstrated that the interpretation of cytological33 and histo-
logical34 findings are routinely downgraded when they are re-
viewed by an expert panel.34,35 All of these factors together
could underestimate or overestimate the results obtained.
In conclusion, the results of this retrospective study suggest
that although the incidence of SIL (cancer precursor lesions)
was higher than expected, the effect of HAART on the control
of HIV replication and of immunological status (200 CD4)
through the follow-up is associated with a reduced incidence of
SIL among HIV women without a background of cervical
pathology. Further prospective studies are necessary to validate
our findings.
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